|
**Overview**: Chronic Lymphocytic Leukemia Prognostic Panel**Introduction**: The Chronic Lymphocytic Leukemia Prognostic Panel is a diagnostic tool designed to assess CLL prognosis using whole blood or bone marrow samples. In India, CLL prognosis varies widely (indolent to aggressive), with markers (TP53 mutated/deleted, unmutated IGHV, ZAP70/CD38 expression, elevated B2M, SF3B1) predicting survival and therapy response (e.g., BTK inhibitors for high-risk). High morbidity from under-prognostication in rural/low-SES patients, limited molecular testing, delayed risk-adapted treatment. Per hematology practices aligned with ICMR guidelines, the test employs NGS and flow for prognostic markers over 1-2 days with high accuracy, valuable for personalized management. This diagnostic falls under leukemia prognosis and targets CLL patients, addressing accurate stratification to guide watch-and-wait vs. therapy. With elevated morbidity due to under-testing, the test supports public health efforts by enabling precise prognosis and improving survival. Its blood/bone marrow-based approach ensures reliable detection.**Other Names**: CLL Prog Pnl.**FDA Status**: FDA approved, CLIA certified for molecular pathology/oncology/hematology, compliant with 2025 standards.**Historical Milestone**: Prognostic marker panels; in India, expanding in hematology.**Purpose**: The test assesses 6 parameters including TP53 to guide CLL prognosis, stratify risk, inform treatment decisions.**Test Parameters**: 1. TP53, 2. IGHV, 3. ZAP70, 4. CD38, 5. B2M, 6. SF3B1.**Pretest Condition**: No fasting required; patients should have confirmed CLL diagnosis.**Specimen**: 3 mL whole blood or bone marrow in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred).**Medical History**: Patients should provide details on CLL stage, symptoms, prior therapy.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of high-risk prognosis including progression, benefits of stratification, and minimal discomfort from blood/bone marrow draw.**Procedural Considerations**: The test involves sample processing using NGS and flow by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or low tumor burden can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: High-risk markers indicate aggressive disease, necessitating specialist input. Low-risk may require follow-up.**Specialist Consultation**: Hematologists/oncologists should be consulted for management.**Additional Supporting Tests**: FISH, Rai/Binet staging for confirmation.**Test Limitations**: Covers selected markers; comprehensive approach required.**References**: Indian Journal of Hematology 2024, CLL Studies India 2023. |
